Archive for Cancer

Cancer Treatment and Cancer Care(CTCA) Job opportunities

There are many ways to beat cancer, is the belief at Cancer Treatment Centers of America, CTCA. They believe that there are hundreds of ways to counteract the disease. For about 30 years of operation, CTCA has a dedication to discovering the best combination of customized treatments for cancer for its patients. A committed staff of surgeons, specialists and oncologists offer advanced treatment for cancer such as operative and safer radiotherapy, more particular surgical options and innovative targeted drug cures.Cancer Treatment Centers of America at Eastern Regional Medical Center in Philadelphia is recruiting a Nocturnist. The preferred candidate should have experience and training with several cancer categories. The hired candidate will take care of grown-up cancer inpatients and attend to the evening inpatient level on a 7-nights-off, 7-nights-on timetable. To qualify for this job candidates must have: DO, MD or external degree equivalent, entitlement for Pennsylvania medical warrant and should be a Board eligible in Internal Medicine.

Cancer Treatment Centers of America invites an interested candidate to apply for the position of an Operator, Switchboard personnel. To qualify for the post mentioned above, one should have a Minimum secondary school diploma or equivalent, robust problem-solving skills, outstanding verbal and written communications expertise, one year minimum of telephone exchange experience and should be a self-motivated and detail accommodator. Job applications are open for the position of Vice President, Growth-Patient Engagement. The selected candidate will be taking tasks of delivering the monthly budget and competent new patient additional figures to the five Cancer Treatment Centers of America in the medical centers of his administrative region. Qualifications for this position include a bachelor’s Degree (MHA, MBA) is strongly needed, an official leadership in using analytics and statistics in an operational problem-solving experience of not less than five years. The preferred candidate is also expected to have demonstrated not less than fifteen years of experience in contact center operations and increasing sales.

Applications for a Dispatcher at Cancer Treatment Centers of America are open. The duties of a Dispatcher includes Preparing patient and guest substantial transportation to and from the hotels, airport, and appointments. He also deals with all scheduled patients’ activities that are sponsored by Cancer Treatment Centers of America. To qualify, one requires to have not less than three years’ experience in driving, three and above years’ experience in customer care services and must have graduated in high school. The candidate Should also pass the Department of Transportation practical test, possess a valid driver’s license for the State of Georgia and a valid Commercial Driver’s License for the State of Georgia having a Passenger Endorsement. Ability to speak fluent Spanish will be an added advantage.Cancer Treatment Centers of America value talent and teamwork. They also consider candidates with a thirst for improvement since the organization believes in creativity and problem solving for its clients.


Omar Boraie and Rutgers University

In order to improve the field of precision medicine at Rutgers University, the Omar Boraie Chair in Genomic Science was established.

According to Newswise, The the State University of New Jersey, also known as Rutgers University, know has a new academic chair. This was possible thanks to Omar Boraie, a prominent real estate developer from New Brunswick, New Jersey. He made a pledge, which consists of donating more than $1.5 million to the University’s 18 chair challenge campaign. The campaign was also possible thanks to a donation of more than $55 million on behalf of an anonymous individual. The Omar Boraie Chair in Genomic science will possibly bring better insights in the field of precision medicine.

Precision medicine, prominently through genomic science,, has been bringing fresh insights in the field of cancer research. It is unconventional and actually more precise in regards to how it deals with tumors, for example. By treating patients according to their unique genetics, oncologists can administer better individualized therapies instead. Genomic Science has been found to be helpful for those that have rare types of cancer. It has also helped people that have become immune to certain types of treatments. Rutgers Cancer Institute, which is part of Rutgers University, was one of the first medical facilities in the United States to implement genomic sequencing in cancer research, something unconventional.

Omar Boraie, a business magnate and financial expert, has also a rigorous background in the scientific field of chemistry. For many years, he has been interested in cancer research. And he hopes too that more people in the future will obtain the benefits of precision medicine. According to Robert S. DiPaola, the current director of Rutgers Cancer Institute, Boraie’s monetary donations will leave a legacy in the medical field.

Shridar Ganesan, who is considered to be one of the best oncologists in the world, will lead the Omar Boraie Chair in Genomic Science. Ganesan, who once did research for Harvard’s medical school, is also a director for transnational science and a professor of medicine for Rutgers University. The medical professional and scientist, other than being honored because of his nomination, thinks that there is still a lot to learn about cancer biology. But Genomic analysis has been proven to be incredibly helpful. Cancer is much more complicated than previously thought. Thus, because genomic analysis is superior in regards to understanding tumors, it must continuously be sought after by the medical community.


Clay Siegall leads way in fight against cancer

Clay Siegall has spent his life dedicated to the research and development of novel cancer treatments. He first became aware of the barbarity of many forms of cancer treatments while he was in college. He decided to focus his career on the search for new, less invasive and less damaging ways to treat, and maybe someday cure the disease.



Combining old and new


After spending 15 years as a leading cancer researcher at Bristol-Meyers-Squibb and the National Cancer Institute, Dr. Siegall founded Seattle Genetics in 1998. The company’s mission was to concentrate on researching and developing a new line of promising anti-cancer drugs called antibody drug conjugates. These are a form of the broader category of drugs known as targeted cancer therapies.


These targeted therapies were developed in response to the often times horrific means by which cancer is treated. Prior to the 2000s, the two main treatment modalities for cancer were killing the cancer cells through such means as radiation and chemotherapy or excision of the tumor. This last option often involves radical surgery, including amputation of limbs and other body parts. Chemotherapy and radiation can be just as nasty, with recipients often having lifelong deficits, such as paresthesia or cardiomyopathy, and visibly accelerated aging, among many other terrible side-effects.


Siegall thought that there was a better way. While most targeted therapies, up until 2000 or so, had involved cytostatic agents, that is, agents which stop further proliferation of cancer cells, Siegall thought that the delivery mechanisms used in targeted therapies could be used to deliver much more potent cytotoxic agents, chemicals which actively kill tumor cells, sending the cancer into remission.


Between 1998 and 2011, Seattle Genetics developed a number of innovative approaches to developing the delivery systems that would take the cytotoxic chemicals directly to the site of the tumor without any systemic release, completely eliminating all of the traditional side-effects of chemotherapy while enhancing anti-cancer effects.


This culminated, in 2011, with the first FDA approval of a viable antibody drug conjugate, Seattle Genetics’ Adcetris. Today, Adcetris and similar drugs are revolutionizing the ways in which cancer is treated across the globe.

An 18-Year-Old Student Discovers Possible Cure for Cancer in Chia Seeds

There have been a lot of expectations put on the new generation of young people who are getting ready to enter the workforce. The world is in crisis, and we need the best and the brightest minds to lead us through this time of trouble, and Oliver Cloutier is going to be one of them. In fact, he already is.

Cloutier is only 18-years-old but has already accomplished more than most by studying chia seeds of all things. The young student had heard about supposed health and nutritional benefits the small seeds provided, so he decided to further investigate the ancient claims.

He extensively studied the history of chia seeds and how it was used in certain practices, some of which dated back thousands of years. And it turns out the ancients knew what hey were talking about. Cloutier found something he never expected when discovering chia seeds contained a molecule which could prove extremely effective at treating cancer.

Specific extracts from chia seeds have special cancer-fighting capabilities by inhibiting cells responsible for creating the disease according to Marcio Alaor BMG. The up-and-coming researcher is busy finding applications to his findings by developing a treatment using the amazing extracts found during his experiments with chia seeds.

The research also landed Cloutier a full college scholarship and first place in the Hydro-Quebec Science Expo last month.